[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AlloSource\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100555451","allomend-acellular-dermal-matrix-allograft-in-pre-pectoral-breast-reconstruction-100555451",false,"NCT06512259","AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction","A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.","Inclusion Criteria:\n\nPatients must meet the following inclusion criteria to participate in this study:\n\n* Diagnosed by a physician and required a single or double mastectomy followed by Pre-Pectoral Breast Reconstruction surgery with the use of AlloMend® Acellular Dermal Matrix allograft;\n* Surgical intervention using AlloMend® Acellular Dermal Matrix allograft was used;\n* Has completed or will complete the anticipated clinically indicated follow-up visits at 2 weeks, 6 weeks, 3 months, and 6 months post-surgical intervention.\n\nExclusion Criteria:\n\nPatients must not meet any of the following criteria to be considered for this clinical trial:\n\n* Did not utilize AlloMend® Acellular Dermal Matrix allograft during pre-pectoral breast reconstruction\n* Did not have post-operative evaluations at the clinical site.","FEMALE","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.",[24],"Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy","RECRUITING","2025-11-20",{"date":28,"type":29},"2025-11-21","ACTUAL",{"date":31,"type":29},"2023-10-19",{"date":33,"type":20},"2026-12-31",{"name":35,"class":36},"AlloSource","INDUSTRY",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100532741","evaluating-cryopreserved-osteochondral-allograft-cores-for-the-treatment-of-osteochondral-lesions-in-the-knee-100532741","NCT06216756","Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee","A Prospective, Open Label, Single-Arm, Multi-Center Study Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee","Inclusion Criteria:\n\n* Patients are ≥12 years and ≤ 60 years of age at the time of surgery.\n* Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e., medication, bracing, physical therapy) and\u002For previous surgical intervention OR unsalvageable lesion that requires transplantation at the discretion of the treating physician.\n* Radiographically diagnosed, by MRI or CT scans, or through arthroscopy, to have a cartilage defect on the femoral condyle between 0.9-8.0 cm2 in size.\n* Will be having an osteochondral transplant procedure.\n* Has a mechanically stable knee or can be mechanically stabilized in the same procedure.\n* Has a normally aligned knee as confirmed by anatomic comparison to contralateral limb, or \\\u003C5° varus or valgus malalignment that has been corrected or will be corrected in same procedure.\n* Ipsilateral knee compartment has intact menisci or requires partial meniscectomy ≤ 50% resulting in stable menisci.\n* Confirmation MRI, CT scan, or arthroscopy obtained pre-operatively within 90 days of surgery\n* Willingness to follow standardized rehabilitation procedures.\n* Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.\n\nExclusion Criteria:\n\n* Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e., \\> than ICRS Grade 2 on the opposing articular surface).\n* Has had a prior osteochondral allograft transplant procedure in the same knee.\n* Will be receiving a meniscus allograft transplantation in the same procedure.\n* Body Mass Index (BMI)of ≥ 35 kg\u002Fm2.\n* Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer) unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.\n* Clinical and\u002For radiographic disease in the affected joint that includes generalized osteoarthritis, gout or a history of gout or pseudo-gout.\n* Active local microbial infection or a systemic infection, including HIV, syphilis, Hepatitis B or Hepatitis C.\n* Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation and\u002For chemotherapy.\n* Unstable cardiovascular, renal, hepatic, endocrine and\u002For pulmonary disease, cancer, or uncontrolled diabetes.\n* Has a history of any inflammatory joint arthropathy.\n* Currently using\u002Fchronic on oral corticosteroids.\n* Received interarticular corticosteroid injection ≤ 90 days prior to surgery.\n* Received hyaluronic acid injections into the joint space ≤ 45 days prior to surgery.\n* Is a female patient who is pregnant.\n* Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his\u002Fher ability to participate in the clinical study.\n* Has a history of substance abuse- (including but not limited to recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and\u002For drug abuse in an in-patient substance abuse program.\n* Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol.\n* Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days.\n* Has any contraindications for MRI.\n* Is having the procedure as part of a Worker's Compensation claim.\n* Is a ward of the state, prisoner, or transient.","ALL","12 Years","60 Years",{"count":49,"type":20},68,"INTERVENTIONAL",[52],"NA","The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.",[55],"Osteochondral Defect",{"date":57,"type":29},"2025-11-25",{"date":59,"type":29},"2024-12-01",{"date":61,"type":20},"2031-03",{"name":35,"class":36},6,""]